Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria

2019 ◽  
Vol 166 ◽  
pp. 224-231 ◽  
Author(s):  
Saba Tahir ◽  
Tariq Mahmood ◽  
Faiqa Dastgir ◽  
Ihsan-ul Haq ◽  
Amir Waseem ◽  
...  
Keyword(s):  
Resistant Bacteria ◽  
Drug Resistant ◽  
Design Synthesis ◽  
Piperazine Derivatives ◽  
Drug Resistant Bacteria

Design, Synthesis, and Antibacterial Activity of Demethylvancomycin Analogues against Drug-Resistant Bacteria

ChemMedChem ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. 976-984 ◽  
Author(s):  
Jun Chang ◽  
Si-Ji Zhang ◽  
Yong-Wei Jiang ◽  
Liang Xu ◽  
Jian-Ming Yu ◽  
...  
Keyword(s):  
Antibacterial Activity ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Design Synthesis ◽  
Drug Resistant Bacteria

Inside Cover: Design, Synthesis, and Antibacterial Activity of Demethylvancomycin Analogues against Drug-Resistant Bacteria (ChemMedChem 6/2013)

ChemMedChem ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. 866-866
Author(s):  
Jun Chang ◽  
Si-Ji Zhang ◽  
Yong-Wei Jiang ◽  
Liang Xu ◽  
Jian-Ming Yu ◽  
...  
Keyword(s):  
Antibacterial Activity ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Design Synthesis ◽  
Drug Resistant Bacteria ◽  
Cover Design

Design, synthesis, and antibacterial evaluation of PFK-158 derivatives as potent agents against drug-resistant bacteria

2021 ◽  
Vol 41 ◽  
pp. 127980
Author(s):  
Wei Wang ◽  
You-Wen Zhang ◽  
Shang-Jiu Hu ◽  
Wei-Ping Niu ◽  
Guo-Ning Zhang ◽  
...  
Keyword(s):  
Resistant Bacteria ◽  
Drug Resistant ◽  
Design Synthesis ◽  
Drug Resistant Bacteria ◽  
Antibacterial Evaluation

Novel Antibiotics from Marine Sources

2011 ◽  
Vol 4 (3) ◽  
pp. 1446-1461 ◽  
Author(s):  
E.A. Martis ◽  
G M Doshi ◽  
G V Aggarwal ◽  
P P Shanbhag
Keyword(s):  
Pharmaceutical Industry ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Terrestrial Life ◽  
New Antibiotics ◽  
Antibiotic Compounds ◽  
New Generation ◽  
Novel Antibiotics ◽  
Untapped Resource

With the emergence of newer diseases, resistant forms of infectious diseases and multi-drug resistant bacteria, it has become essential to develop novel and more effective antibiotics. Current antibiotics are obtained from terrestrial life or made synthetically from intermediates. The ocean represents virtually untapped resource from which novel antibiotic compounds can be discovered. It is the marine world that will provide the pharmaceutical industry with the next generation of antibiotics. Marine antibiotics are antibiotics obtained from marine organisms. Scientists have reported the discovery of various antibiotics from marine bacteria (aplasmomycin, himalomycins, and pelagiomycins), sponges (Ara C, variabillin, strobilin, ircinin-1, aeroplysin, 3,5-dibromo-4-hydroxyphenylacetamide), coelenterates (asperidol and eunicin), mollusks (laurinterol and pachydictyol), tunicates (geranylhydroquinone and cystadytins), algae (cycloeudesmol, aeroplysinin-1(+), prepacifenol and tetrabromoheptanone), worms (tholepin and 3,5-dibromo-4-hydroxybezaldehyde), and actinomycetes (marinomycins C and D). This indicates that the marine environment, representing approximately half of the global diversity, is an enormous resource for new antibiotics and this source needs to be explored for the discovery of new generation antibiotics. The present article provides an overview of various antibiotics obtained from marine sources.

Re-challenging antibiotic resistance with Daniel Berman

2020 ◽  
Author(s):  
Daniel Berman
Keyword(s):  
Bacterial Infections ◽  
Point Of Care ◽  
Healthcare Setting ◽  
Rapid Diagnostic Tests ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Global Threat ◽  
The Right ◽  
Point Of Care Tests

How can we prevent the rise of resistance to antibiotics? In this video, Daniel Berman,  Nesta Challenges, discusses the global threat of AMR and how prizes like the Longitude Prize can foster the development of rapid diagnostic tests for bacterial infections, helping to contribute towards reducing the global threat of drug resistant bacteria. Daniel outlines how accelerating the development of rapid point-of-care tests will ensure that bacterial infections are treated with the most appropriate antibiotic, at the right time and in the right healthcare setting.

Use of proton pump inhibitors and cholangitis complicated with multi‐drug resistant bacteria

2021 ◽  
Author(s):  
Ryunosuke Hakuta ◽  
Yousuke Nakai ◽  
Tsuyoshi Hamada ◽  
Yusuke Nomura ◽  
Tomotaka Saito ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria
Sign in / Sign up

Export Citation Format

Share Document